UK Markets closed

Sinopharm Group Co. Ltd. (X2S.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
2.2580+0.0600 (+2.73%)
As of 12:35PM CEST. Market open.

Sinopharm Group Co. Ltd.

Sinopharm Group Building
No. 385, East Longhua Road Huangpu District
Shanghai 200023
China

https://www.sinopharmgroup.com.cn

Sector(s)Healthcare
IndustryMedical Distribution
Full-time employees113,234

Key executives

NameTitlePayExercisedYear born
Mr. Qingming YuExec. Chairman998.24kN/A1964
Mr. Yong LiuPres & Exec. Director971.75kN/A1969
Mr. Xiuchang JiangCFO & VPN/AN/A1964
Ms. Xiaojuan LiChief Financial OfficerN/AN/A1976
Mr. Yijian WuCompany Sec.N/AN/A1970
Mr. Wanyong LianVPN/AN/A1971
Mr. Shuangjun XuNon-Exec. VPN/AN/A1969
Mr. Maisong CaiVPN/AN/A1970
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Corporate governance

Sinopharm Group Co. Ltd.’s ISS governance QualityScore as of 1 May 2022 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.